Ισραήλ - Εβραϊκά - Ministry of Health

teva pharmaceutical industries ltd, israel - spironolactone - טבליה - spironolactone 100 mg - spironolactone - spironolactone - edematous conditions: congestive heart failure; cirrosis of the liver accompanied by edema and/or ascites nephrotic syndrome. essential hypertention. primary hyperaldostronism. hypokalemia.

Ισραήλ - Εβραϊκά - Ministry of Health

teva israel ltd - spironolactone - טבליה - spironolactone 100 mg - spironolactone - spironolactone - edematous conditions: congestive heart failure; cirrosis of the liver accompanied by edema and/or ascites nephrotic syndrome. essential hypertention. primary hyperaldostronism. hypokalemia.

Ισραήλ - Εβραϊκά - Ministry of Health

teva pharmaceutical industries ltd, israel - atenolol - טבליה - atenolol 100 mg - atenolol - atenolol - management of angina pectoris and hypertension,including hypertension of renal origin. late intervention after acute myocardial infarction.

Ισραήλ - Εβραϊκά - Ministry of Health

padagis israel agencies ltd, israel - labetalol hydrochloride - טבליה - labetalol hydrochloride 100 mg - labetalol - labetalol - treatment of all grades of hypertension (mild, moderate and severe) when oral antihypertensive therapy is desirable.

Ισραήλ - Εβραϊκά - Ministry of Health

dexcel pharma technologies ltd - losartan potassium - קפליות - losartan potassium 100 mg - losartan - losartan - hypertension. losardex is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to losardex is not recommended. renal protection in type-2 diabetic patients with proteinuria: losardex is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losardex is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of losardex on the primary deposite endpoi

Ισραήλ - Εβραϊκά - Ministry of Health

dexcel pharma technologies ltd - losartan potassium - קפליות - losartan potassium 100 mg - losartan - losartan - hypertension. losardex is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to losardex is not recommended.renal protection in type-2 diabetic patients with proteinuria: losardex is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losardex is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of losardex on the primary deposite endpoin

Ισραήλ - Εβραϊκά - Ministry of Health

bioavenir ltd - losartan as potassium 100 mg - tablets - losartan - hypertension: losartan is indicated for the treatment of heart failure ( nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to tiasar is not recommended. renal protection in type - 2 diabetic patients with proteinuria: losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease ( need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrphy. losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrphy. the benefit of tiasar on the primary deposite end poin

Ισραήλ - Εβραϊκά - Ministry of Health

pfizer pharmaceuticals israel ltd - medroxyprogesterone acetate 100 mg - tablets - medroxyprogesterone - progestogen indicated for the treatment of certain hormone dependent neoplasms.

Ισραήλ - Εβραϊκά - Ministry of Health

cts ltd - progesterone - קפסולות - progesterone 100 mg - progesterone - progesterone - vaginal or oral addministration: disorders related to progesterone deficit in particular menopause ( in association with estrogen therapy).vaginal administration: progesterone substitution for ovary deprived women in situation of total progesterone deficiency. supplementation of the luteal phase during in vitro fertilization cycles. supplementation of the luteal phase during spontaneous or induced cycles, in cases of hypofertility or primary or secondary ovarain failure, particulary through dysovulation. in cases of threatning abortion or prevention of repeated abortions due to proven luteal insufficiency. for all other progesterone indications, in the case of : adverse events due to progesterone, contraindication of the oral route of administration hepatopathy.

Ισραήλ - Εβραϊκά - Ministry of Health

bioavenir ltd, israel - sildenafil as citrate - טבליות מצופות פילם - sildenafil as citrate 100 mg - sildenafil - sildenafil - treatment of erectile dysfunction.